Loading news...
The biotech published its last set of financials for 2025. Its quarterly revenue and adjusted profitability declined, yet both still topped the consensus analyst estimates.
Revenue: Total revenue for the full year 2025 was $9.9 billion, up 2% versus 2024.Non-GAAP EPS: Fourth quarter non-GAAP diluted EPS was $1.99; full year non-GA
Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS outlook despite revenue pressure.
The headline numbers for Biogen (BIIB) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.
Biogen Inc. (BIIB) came out with quarterly earnings of $1.99 per share, beating the Zacks Consensus Estimate of $1.61 per share. This compares to earnings of $3.44 per share a year ago.
Biogen says it expects revenue to fall in 2026 as its multiple sclerosis therapies continue to struggle.
Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines and its Alzheimer's treatment Leqembi as older multiple sclerosis drugs battle pressure from cheaper versions.
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Nature Medicine published results from the Phase 2/3 DEVOTE study evaluating the high-dose regimen of nusinersen, comprised of 50 mg/5 mL loading and 28 mg/5 mL maintenance doses, in spinal muscular atrophy (SMA). The high-dose regimen of nusinersen offers a more rapid loading regimen, two 50 mg doses 14 days apart, and a higher maintenance regimen, 28 mg, every 4 months, compared to the 12 mg nusinersen regimen (SPINRAZA®). The results showed the safety and effectiveness of the high-dose regimen of nusinersen across a broad range of people living with SMA, irrespective of age, prior treatment experience, and baseline functional status.
It's been an interesting start to the year, with plenty of geopolitical developments for investors to unpack.
Biogen heads into Q4 earnings with MS drug pressure, while Leqembi and Skyclarys' growth could help offset declines ahead of its Feb. 6 report.
National Pension Service raised its holdings in Biogen Inc. (NASDAQ: BIIB) by 4.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 285,202 shares of the biotechnology company's stock after purchasing an additional 12,147 shares during the quarter. National Pension Service owned 0.19%
New York State Common Retirement Fund boosted its stake in Biogen Inc. (NASDAQ: BIIB) by 2.3% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 143,465 shares of the biotechnology company's stock after acquiring an additional 3,220 shares during the period. New York
Great Lakes Advisors LLC acquired a new stake in shares of Biogen Inc. (NASDAQ: BIIB) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,479 shares of the biotechnology company's stock, valued at approximately $1,328,000. Several other institutional
Biogen Inc. (NASDAQ: BIIB - Get Free Report) has received an average rating of "Hold" from the twenty-seven brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have assigned a buy rating to the company. The average
Privium Fund Management B.V. raised its stake in shares of Biogen Inc. (NASDAQ: BIIB) by 153.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 51,925 shares of the biotechnology company's stock after buying an additional 31,425 shares during the quarter. Biogen
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BIIB secures FDA's Breakthrough Therapy status for litifilimab in cutaneous lupus, backed by phase II results, while advancing phase III and broader lupus studies.
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activity Litifilimab has the potential to be a first-in-class therapy targeting blood dendritic cell antigen 2 (BDCA2) in CLE, a chronic autoimmune skin disease that has a substantial impact on the daily life of patients, and may result in permanent scarring and disfigurement FDA Breakthrough Therapy Designation is granted to expedite the development and review of drugs for serious diseases CAMBRIDGE, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment of cutaneous lupus erythematosus (CLE).